Abstract：
OBJECTIVE: There is increasing incidence of renal cell carcinoma (RCC) with multiple treatment options currently available. The purpose of this review is to outline patient selection and technical approaches and present the current literature for percutaneous ablation of T1b (4.1-7 cm) RCC.
RESULTS: An increasing number of retrospective studies and meta-analyses have evaluated the use of percutaneous ablation for T1b RCC. Overall, these studies tend to show that percutaneous ablation in this patient population is feasible. However, rates of major adverse events and local recurrence after percutaneous ablation for T1b RCC are both higher than when ablation is used for smaller tumors. As such, a multi-disciplinary, patient-centered approach is required. Due to the increasing literature in this area, the most recent National Comprehensive Cancer Network (NCCN) guidelines include percutaneous ablation as an option for non-surgical patients with T1b RCC.
RESULTS: An increasing number of retrospective studies and meta-analyses have evaluated the use of percutaneous ablation for T1b RCC. Overall, these studies tend to show that percutaneous ablation in this patient population is feasible. However, rates of major adverse events and local recurrence after percutaneous ablation for T1b RCC are both higher than when ablation is used for smaller tumors. As such, a multi-disciplinary, patient-centered approach is required. Due to the increasing literature in this area, the most recent National Comprehensive Cancer Network (NCCN) guidelines include percutaneous ablation as an option for non-surgical patients with T1b RCC.
摘要：
目的：肾细胞癌（RCC）的发病率正在增加，目前有多种治疗选择。这篇综述的目的是概述患者的选择和技术方法，并介绍T1b（4.1-7cm）RCC经皮消融的最新文献。
结果：越来越多的回顾性研究和荟萃分析评估了经皮消融治疗T1bRCC的应用。总的来说,这些研究倾向于表明，经皮消融在这一患者人群中是可行的。然而,T1b型RCC经皮消融术后的主要不良事件和局部复发率均高于较小肿瘤的消融术.因此，一个多学科,需要以患者为中心的方法。由于这方面的文献越来越多,最新的国家综合癌症网络(NCCN)指南将经皮消融作为T1bRCC非手术患者的一种选择.
结果：越来越多的回顾性研究和荟萃分析评估了经皮消融治疗T1bRCC的应用。总的来说,这些研究倾向于表明，经皮消融在这一患者人群中是可行的。然而,T1b型RCC经皮消融术后的主要不良事件和局部复发率均高于较小肿瘤的消融术.因此，一个多学科,需要以患者为中心的方法。由于这方面的文献越来越多,最新的国家综合癌症网络(NCCN)指南将经皮消融作为T1bRCC非手术患者的一种选择.
